Ridinilazole - Summit Therapeutics
Alternative Names: SMT-19969Latest Information Update: 28 Mar 2024
At a glance
- Originator Summit plc
- Developer Summit Therapeutics
- Class Antibacterials; Benzimidazoles; Pyridines; Small molecules
- Mechanism of Action Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Clostridium difficile infections